New drug combo aims to extend life for advanced liver cancer patients
NCT ID NCT07226063
Summary
This study is for people with advanced liver cancer who are already receiving durvalumab after initial treatment with tremelimumab and durvalumab. Researchers want to see if adding an experimental oral drug called zanzalintinib to the ongoing durvalumab treatment helps people live longer by better controlling the cancer. The main goal is to measure how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.